Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab for prevention of vaso-occlusive episodes in sickle cell disease
2022-502542-28-00Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Crovalimab adjunct arm with Placebo adjunct arm (2 arms). Primary endpoint: Annualized rate of medical facility vaso-occlusive episodes (AVR). Started Dec 2021; status: completed.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2022-502542-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502542-28-00.